Tesamorelin: A review of its use in the management of HIV-associated lipodystrophy

Drugs

Volumn 71, Issue 8, 2011, Pages 1071-1091

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; General; HIV associated lipodystrophy syndrome; Tesamorelin

Indexed keywords

ADIPONECTIN; AMINO TERMINAL TELOPEPTIDE; ANABOLIC AGENT; ANDROGEN; C REACTIVE PROTEIN; CHOLESTEROL; CORTISONE ACETATE; CYTOCHROME P450 ISOENZYME; GLITAZONE DERIVATIVE; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PHENAZONE; PLACEBO; PREDNISONE; RECOMBINANT GROWTH HORMONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; SOMATOMEDIN C; TESAMORELIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ARTHRALGIA; BACKACHE; BODY COMPOSITION; BODY IMAGE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIMB PAIN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; METABOLIC PARAMETERS; MYALGIA; PERIPHERAL EDEMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SUBCUTANEOUS FAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRUNK; UPPER RESPIRATORY TRACT INFECTION; WAIST CIRCUMFERENCE;

GROWTH HORMONE-RELEASING HORMONE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958779804     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202240-000000000-00000     Document Type: Review

References (57)

1. Wierzbicki AS, Purdon SD, Hardman TC, et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res & Opin 2008; 24 (3): 609-24. (Pubitemid 351428972)
2. Lohse N, Hansen AB, Gerstoft J, et al. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007 Sep; 60 (3): 461-3. (Pubitemid 47303950)
3. Benedini S, Terruzzi I, Lazzarin A, et al.Recombinant human growth hormone: rationale for use in the treatment of HIVassociated lipodystrophy. Biodrugs 2008; 22 (2): 101-12. (Pubitemid 351419122)
4. Gazzard BG, Anderson J, Babiker A, et al. on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008 Oct; 9 (8): 563-608.
5. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999 Mar 11; 13 (4): 465-71.
6. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitorassociated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 Jun 19; 353 (9170): 2093-9. (Pubitemid 29278477)
7. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment ofHIV-1 infection. AIDS 2001 May 4; 15 (7): 847-55. (Pubitemid 32424388)
8. Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis 2011 Feb; 24 (1): 43-9.
9. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001 Feb; 86 (2): 504-10. (Pubitemid 32207451)
10. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007 Jul 1; 45 (3): 286-97. (Pubitemid 47012375)
11. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008 Aug 6; 300 (5): 509-19.
12. Koutkia P, Canavan B, Breu J, et al. Growth hormonereleasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004 Jul 14; 292 (2): 210-8. (Pubitemid 38917998)
13. Theratechnologies Inc. Egrifta- (tesamorelin for injection): US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/022505s000lbl.pdf [Accessed 2011 Feb 8].
14. Theratechnologies. FDA approves Egrifta- (tesamorelin for injection): the first and only treatment for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [media release]. 2010 Nov 11 [online]. Available from URL: http://www.theratech.com/en/investor-relat ions/news.php?id=391.
15. Michaud SE, Abolfathi Z, Potvin D, et al. Pharmacokinetic/ pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone-releasing factor analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations [poster no. P3-641]. 91st Annual Meeting of the Endocrine Society; 2009 Jun 10-13; Washington, DC.
16. Mamputu JC, Soulban G, Falutz J. Effects of tesamorelin, a growth hormone-releasing factor (GRF) analogue, on bone turnover markers in HIV-infected patients with excess abdominal fat [abstract no. 834 plus poster presentation]. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston (MA).
17. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2010/022505Orig1s000ClinPharmR.pdf [Accessed 2011 Feb 9].
18. Center for Drug Evaluation and Research. Pharmacology review(s) [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/nda/2010/ 022505Orig 1s000PharmR.pdf [Accessed 2011 Feb 9].
19. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009 Apr; 30 (2): 152-77.
20. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007 Jan; 100 (1): 49-58. (Pubitemid 46051443)
21. Falutz J, Allas S, Kotler D, et al. Aplacebo-controlled, doseranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005 Aug 12; 19 (12): 1279-87. (Pubitemid 41224897)
22. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011 Jan; 96 (1): 150-8.
23. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007 Dec 6; 357 (23): 2359-70. (Pubitemid 350223390)
24. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010 Mar 1; 53 (3): 311-22.
25. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008 Sep 12; 22 (14): 1719-28.
26. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010 Sep; 95 (9): 4291-304.
27. Center for Drug Evaluation and Research. Medical review( s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 022505Orig1s000MedR.pdf [Accessed 2011 Feb 15].
28. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 Jun; 23 (6): 579-93.
29. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32 (1): 193-203.
30. Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on inflammatory markers in HIV Patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. Epub 2011 Apr 21.
31. Vincent G, Teng S, Ducharme MP, et al. Impact of tesamorelin (TH9507), a stabilized growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers [poster no. P178]. 18th Annual Canadian Conference on HIV/AIDS Research; 2009 Apr 23-26; Vancouver (BC).
32. Zoltowska M, Morin J, Glyman S, et al. Efficacy and longterm safety of tesamorelin (TH9507), a growth hormonereleasing factor (GRF) analogue, in sub-populations of HIV-infected patients with excess abdominal fat [poster no. H-228]. 50th International Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12-15; Boston (MA).
33. Falutz J, Mamputu JC, Marsolais C, et al. Atherogenic lipid profile in treated HIV patients with increased visceral adiposity: association with more severe CVD risk parameters and response to tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue [poster no. 713]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal (QC).
34. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 2007 May; 85 (5): 1197-202. (Pubitemid 46740459)
35. Pouliot MC, Despré s JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994 Mar 1; 73 (7): 460-8. (Pubitemid 24096208)
36. Savgan-Gurol E, Bredella M, Russell M, et al. Waist to hip ratio and trunk to extremity fat (DXA) are better surrogates for IMCL and for visceral fat respectively than for subcutaneous fat in adolescent girls. Nutr Metab (Lond) 2010; 7: 86.
37. Center for Drug Evaluation and Research. Summary review [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 022505Orig1s000SumR.pdf [Accessed 2011 Feb 22].
38. Guaraldi G, Murri R, Orlando G, et al. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev 2008 Jul 30; 10 (3): 152-61.
39. Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS 2008 Jul; 22 (7): 577-85. (Pubitemid 352040052)
40. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2009 Apr; 30 (7): 850-6.
41. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008 May 1; 48 (1): 44-52.
42. Moyle G, Moutschen M, Martinez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010; 12 (1): 3-14.
43. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008 Feb; 9 (2): 72-81. (Pubitemid 351232645)
44. European AIDS Clinical Society. Guidelines (version 5-2) [online]. Available from URL: http://www.europeanaidsclinicalsociety.org/guidelinespdf/ EACS-EuroGuidelines-FullVersion.pdf [Accessed 2011 Feb 17].
45. US Department of Health and Human Services. Lipodystrophy [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/Lipodystrophy-FS- en.pdf [Accessed 2011 Feb 17].
46. Porter SA, Massaro JM, Hoffmann U, et al. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care 2009 Jun; 32 (6): 1068-75.
47. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004 Mar; 89 (3): 1200-6. (Pubitemid 38368413)
48. Masiá M, Padilla S, Garcia N, et al. Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antivir Ther 2010; 15 (1): 101-10.
49. Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989 Feb; 79 (2): 287-91. (Pubitemid 19055498)
50. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005 May 1; 39 (1): 44-54. (Pubitemid 40617018)
51. Lekakis J, Tsiodras S, Ikonomidis I, et al. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Sci (Lond) 2008 Sep; 115 (6): 189-96.
52. Lekakis J, Ikonomidis I. Cardiovascular complications of AIDS. Curr Opin Crit Care 2010 Oct; 16 (5): 408-12.
53. Deeks SG. Perspective: immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009; 17 (4): 118-23.
54. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010 Nov 20; 28 (33): 4985-95.
55. Mateo MG, Gutiérrez MDM, Domingo P, et al. Tesamorelin for the treatment of excess abdominal fat in HIV-1 patients with lipodystrophy. Expert Rev Endocrinol Metab 2011; 6 (1): 21-30.
56. Henricsson M, Berntorp K, Fernlund P, et al. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002 Feb; 25 (2): 381-5. (Pubitemid 41079640)
57. Falutz J. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies. Curr Opin Clin Nutr Metab Care 2011 May; 14 (3): 255-60